BioNTech SE ADR (BNTX)

followers · Follow

Sector:	HEALTH CARE
Industry:	BIOTECHNOLOGY & LIFE SCIENCES
SIC:	BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:	Ugur Sahin
Employees:	3,080
Web site:	biontech.de
AN DER GOLDGRUBE 12, MAINZ, 2M, 55131 0049613190847081

	All 13F Filers	Prior	Change	Hedge Funds ¹	Prior	Change

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma. It also develops neoantigen specific immunotherapy, such as Autogene cevumeran (BNT122) and BNT141.

Please log in first to see chart

BioNTech SE ADR YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Shareholders (13F, 13D/G)

Current Mutual Fund/ETF Holders

Active 13D/G Filings

SEC Filings

Insiders

Short Positions

Congress

Proposed Sales

Comments and Updates

To Excel | To CSV | To TSV

Investor	History	Shares Held or Principal Amt	Market Value	% of Portfolio	Previous % of Portfolio	Rank	Change in Shares	% Ownership	Qtr 1st Owned	Est. Avg Price	Source	Source Date	Date Reported
No data available